Bausch + Lomb (NYSE:BLCO) Has A Somewhat Strained Balance Sheet

Simply Wall StJun 26 22:12

Why Is Clearside Biomedical Stock Gaining Today?

BenzingaJun 26 00:54

Wells Fargo Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Announces Target Price $23

Wells Fargo analyst Larry Biegelsen maintains $Bausch + Lomb Corp.(BLCO.US)$ with a buy rating, and sets the target price at $23.According to TipRanks data, the analyst has a success rate of 59.9% and

Futu NewsJun 24 20:31 · Ratings

Bausch + Lomb Announces Presentation of New Data at the European Dry Eye Society 2024 Congress

BusinesswireJun 17 19:00

Wells Fargo Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $23

Wells Fargo analyst Larry Biegelsen maintains $Bausch + Lomb Corp.(BLCO.US)$ with a buy rating, and maintains the target price at $23.According to TipRanks data, the analyst has a success rate of 60.1

Futu NewsJun 11 17:32 · Ratings

Bausch + Lomb INFUSE for Astigmatism Silicone Hydrogel Daily Disposable Contact Lenses Introduced in the United States

BusinesswireJun 10 19:00